XFOR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

1.90M

+237.48%

-4.290

+102.61%

2.27M

+305.71%

-2.990

-44.63%

-2.643

-55.94%

Estimates Revision

The market is revising No Change the revenue expectations for X4 Pharmaceuticals, Inc. (XFOR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 29.45%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+29.45%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast XFOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XFOR is 57.75 USD with a low forecast of 7.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.00

Averages

57.75

High

120.00

Current: 0.000

Low

7.00

Averages

57.75

High

120.00

Stifel

James Condulis

NULL -> Buy

maintain

$10

2025-12-05

Reason

Stifel

James Condulis

Price Target

$10

2025-12-05

maintain

NULL -> Buy

Reason

Stifel analyst James Condulis raised the firm's price target on X4 Pharmaceuticals to $10 from $7.50 and keeps a Buy rating on the shares as the firm transferred coverage of the stock. The firm's "bullish thesis" is based on a view that, after a significant transformation of the company in recent months, X4 "finally has the right team" to develop, launch and sell a hematology-focused asset and necessary capital and strategy through a potential launch in 2028, the new analyst tells investors.

H.C. Wainwright

NULL -> Buy

maintain

2025-11-10

Reason

H.C. Wainwright

Price Target

2025-11-10

maintain

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on X4 Pharmaceuticals to $5 from $3.50 and keeps a Buy rating on the shares post the Q3 report. The company executed a corporate restructuring to ensure long-term growth, the analyst tells investors in a research note.

Stifel

Buy

downgrade

2025-11-05

Reason

Stifel

Price Target

2025-11-05

downgrade

Buy

Reason

Stifel lowered the firm's price target on X4 Pharmaceuticals to $7.50 from $9 and keeps a Buy rating on the shares. The firm updated the company's model post the earnings report and corporate update. The reduced target reflects revised financing assumptions, including the impact of X4's October financing, the analyst tells investors in a research note.

Stifel

Stephen Willey

Buy

downgrade

$30 -> $9

2025-08-29

Reason

Stifel

Stephen Willey

Price Target

$30 -> $9

2025-08-29

downgrade

Buy

Reason

Stifel analyst Stephen Willey lowered the firm's price target on X4 Pharmaceuticals to $9 from $30 and keeps a Buy rating on the shares following "a number of significant changes" over the past couple of weeks, most notably the "complete overhaul" of the senior leadership team and another recapitalization with the $85M PIPE deal. These changes increase the likelihood mavorixafor is "afforded the opportunity to fulfill its potential" in chronic neutropenia, which the firm believes to be "a multi-billiondollar addressable market opportunity of significant unmet medical need," the analyst tells investors.

H.C. Wainwright

Swayampakula Ramakanth

Buy

downgrade

2025-08-13

Reason

H.C. Wainwright

Swayampakula Ramakanth

Price Target

2025-08-13

downgrade

Buy

Reason

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on X4 Pharmaceuticals to $3.50 from $7 and keeps a Buy rating on the shares. The firm updated the company's model to reflect the Q2 report and private placement expected to close on August 13. The capital raised strengthens the balance sheet and aids in meeting the Hercules Loan covenant obligations, the analyst tells investors in a research note.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$1.5

2025-03-27

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$1.5

2025-03-27

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for X4 Pharmaceuticals Inc (XFOR.O) is -0.52, compared to its 5-year average forward P/E of -1.98. For a more detailed relative valuation and DCF analysis to assess X4 Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.98

Current PE

-0.52

Overvalued PE

-0.47

Undervalued PE

-3.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

122.88

Current PS

3.52

Overvalued PS

373.99

Undervalued PS

-128.23

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 9661.69% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 9661.69% over the last month.

Sold

Bought

XFOR News & Events

Events Timeline

No data

News

8.5

2025-12-24Benzinga

Sanofi Acquires Dynavax for $15.50 per Share, Totaling $2.2 Billion

8.5

2025-11-24Yahoo Finance

Examining X4 Pharmaceuticals' Story Following Leadership Transitions and Recent Funding

5.0

2025-10-28NASDAQ.COM

Insider Buying Update for Tuesday, October 28: CRMD and XFOR

People Also Watch

Frequently Asked Questions

What is X4 Pharmaceuticals Inc (XFOR) stock price today?

The current price of XFOR is 4 USD — it has decreased -0.99 % in the last trading day.

What is X4 Pharmaceuticals Inc (XFOR)'s business?

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

What is the price predicton of XFOR Stock?

What is X4 Pharmaceuticals Inc (XFOR)'s revenue for the last quarter?

X4 Pharmaceuticals Inc revenue for the last quarter amounts to 28.81M USD, decreased % YoY.

What is X4 Pharmaceuticals Inc (XFOR)'s earnings per share (EPS) for the last quarter?

X4 Pharmaceuticals Inc. EPS for the last quarter amounts to 1.20 USD, decreased -115.44 % YoY.

What changes have occurred in the market's expectations for X4 Pharmaceuticals Inc (XFOR)'s fundamentals?

How many employees does X4 Pharmaceuticals Inc (XFOR). have?

X4 Pharmaceuticals Inc (XFOR) has 143 emplpoyees as of January 10 2026.

What is X4 Pharmaceuticals Inc (XFOR) market cap?

Today XFOR has the market capitalization of 112.54M USD.